ACM
IMDX

ACT Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

ACT Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$241K Hold
16,500
– – 0.33% 34
2022
Q2 		$297K Hold
16,500
– – 0.42% 35
2022
Q1 		$492K Hold
16,500
– – 0.52% 34
2021
Q4 		$716K Hold
16,500
– – 0.52% 37
2021
Q3 		$1.18M Hold
16,500
– – 0.61% 34
2021
Q2 		$1.9M Buy
+16,500
New +$1.61M 0.97% 25

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

ACT Capital Management's IMDX Position: Q3 2022 in Review

ACT Capital Management held its Insight Molecular Diagnostics (IMDX) position steady in Q3 2022 at 16,500 shares worth $241K. The position accounts for 0.33% of the portfolio, ranked #34.

ACT Capital Management first reported a position in IMDX in Q2 2021 and has held it in 6 quarters since. The position peaked at $1.9M in Q2 2021. 65 funds tracked by Wall St. Rank hold IMDX as of Q3 2022.

  • ACT Capital Management held 16,500 shares of Insight Molecular Diagnostics worth $241K as of Q3 2022.
  • ACT Capital Management left its Insight Molecular Diagnostics share count unchanged in Q3 2022.
  • Insight Molecular Diagnostics made up 0.33% of ACT Capital Management's portfolio in Q3 2022, its #34 holding.
  • ACT Capital Management first reported a position in Insight Molecular Diagnostics in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Insight Molecular Diagnostics position peaked at $1.9M in Q2 2021.
  • 65 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.